PROFILBARU.COM

	Cansino
Typ	Börsnoterat företag
Säte	401-420 Biomedical Park, 185 South Avenue, Teda West District, Tianjin, Kina
Bransch	Vaccintillverkning
Historik
Grundat	2009

Cansino Biologics Inc., i marknadsföringssyfte skrivet CanSino, (kinesiska: 康希诺生物, Kāngxīnuò Shēngwù) är en kinesisk vaccintillverkare. Det är sedan 2019 noterat på Hongkongbörsen.^[1]

Cansino Biologics grundades 2009 i Tianjin av de fyra kinesiska och kanadensiska vetenskapsmännen Yu Xuefeng, Zhu Tao, Qiu Dongxu och Helen Mao Huihua.^[1]

Företaget har tillsammans Institute of Biotechnology vid Academy of Military Medical Sciences inom Kinas armé och National Research Council i Kanada tagit fram ett ebolavaccin.

Vaccin mot covid-19

Cansino har arbetat med Institute of Biotechnology vid Academy of Military Medical Sciences med utveckling av ett covid-19-vaccin. Företaget träffade i mars 2020 också avtal med National Research Council om samarbete för att utveckla den adenovirusbaserade covid-19-vaccinkandidaten Ad5-nCoV, med avsikt att genomföra kliniska tester i Kanada.^[2]^[3]^[3]

Källor

Noter

^ [a b] Ng, Eric (25 juli 2018). ”Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal”. South China Morning Post. https://www.scmp.com/business/article/2156867/chinese-vaccine-maker-cansino-faces-tough-ipo-sell-wake-changsheng-bio. Läst 7 juli 2020.
^ DeArment, Alaric (13 maj 2020). ”CanSino Biologics may start clinical development of Covid-19 vaccine in Canada”. MedCity News. https://medcitynews.com/2020/05/cansino-biologics-may-start-clinical-development-of-covid-19-vaccine-in-canada/. Läst 7 juli 2020.
^ [a b] Canada, National Research Council. ”The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19”. www.newswire.ca. https://www.newswire.ca/news-releases/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19-816213726.html. Läst 7 juli 2020.

Externa länkar

Cansino Biotechs webbplats

[scmp2018-1] [a b] Ng, Eric (25 juli 2018). ”Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal”. South China Morning Post. https://www.scmp.com/business/article/2156867/chinese-vaccine-maker-cansino-faces-tough-ipo-sell-wake-changsheng-bio. Läst 7 juli 2020.

[2] DeArment, Alaric (13 maj 2020). ”CanSino Biologics may start clinical development of Covid-19 vaccine in Canada”. MedCity News. https://medcitynews.com/2020/05/cansino-biologics-may-start-clinical-development-of-covid-19-vaccine-in-canada/. Läst 7 juli 2020.

[newswire_816213726-3] [a b] Canada, National Research Council. ”The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19”. www.newswire.ca. https://www.newswire.ca/news-releases/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19-816213726.html. Läst 7 juli 2020.

[1]

[2]

[3]